BCA
BHVN

Berman Capital Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Berman Capital Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$13K Buy
97
+68
+234% +$8.49K ﹤0.01% 1116
2021
Q2 		$2K Buy
29
+15
+107% +$1.22K ﹤0.01% 1676
2021
Q1 		$0 Hold
14
– – ﹤0.01% 1988
2020
Q4 		$1K Hold
14
– – ﹤0.01% 1650
2020
Q3 		$0 Sell
14
-16
-53% -$1.05K ﹤0.01% 1881
2020
Q2 		$2K Buy
+30
New +$1.6K ﹤0.01% 1363

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Berman Capital Advisors's BHVN Position: Q3 2021 in Review

Berman Capital Advisors increased its Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stake by 234% in Q3 2021, buying an estimated $8.49K and bringing the position to 97 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #1116.

Berman Capital Advisors first reported a position in BHVN in Q2 2020 and has held it in 6 quarters since. 249 funds tracked by Wall St. Rank hold BHVN as of Q3 2021.

  • Berman Capital Advisors held 97 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $13K as of Q3 2021.
  • Berman Capital Advisors bought 68 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2021, an estimated $8.49K.
  • Biohaven Pharmaceutical Holding Company Ltd. made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1116 holding.
  • Berman Capital Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and has held it in 6 quarters since.
  • 249 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.